Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Anavex Life Sciences Corp.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL). Investors who purchased Anavex securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Anavex has violated federal securities laws.
Anavex Investigation Details
On March 25, 2026, Anavex issued a press release “announc[ing] that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer’s disease in adults, which had been under review by the European Medicines Agency (EMA).” The press release said that “[t]he decision to withdraw the application follows feedback from the EMA’s Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time.” On this news, Anavex’s stock price fell $1.45 per share, or 34.61%, to close at $2.74 per share on March 25, 2026.
What’s Next for Anavex Investors?
If you are aware of any facts relating to this investigation or purchased Anavex securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
AVXL — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”